Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

Marije M. Löwik, Ming Kai Lam, Hanim Sen, Kenneth Tandjung, K. Gert van Houwelingen, Frits H.A.F. de Man, Martin G. Stoel, J. (Hans) W. Louwerenburg, Gerard C.M. Linssen, Carine J.M. Doggen, Clemens von Birgelen
2015 EuroIntervention  
Aims: To assess three-year clinical outcome following randomised use of the second-generation Resolute zotarolimus-eluting stent (ZES) and the XIENCE V everolimus-eluting stent (EES). For Resolute ZES and randomised use, outcome data ≥3 years are relatively scarce.
doi:10.4244/eijy14m08_11 pmid:25136888 fatcat:kvadzk5ukvgmfl66ajjhi4mgvq